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Case ReportsReoperative ‘‘valve-in-valve’’ transapical transcatheter mitral
valve replacement in a high-risk patient with a recent transapical
transcatheter aortic valve replacement and a degenerated
bioprosthetic mitral valveAndreas R. de Biasi, MD,a Shing-Chiu Wong, MD,b and Arash Salemi, MD,a New York, NYTransapical transcatheter aortic valve replacement (TA-
AVR) can safely be performed in high-risk patients who are
not candidates for conventional replacement. However, using
the transapical transcatheter (TA) approach as a reoperative
strategy in patients who have undergone previous TA valve
surgery has not been well described. We therefore report
the first known case of a patient who recently underwent
TA-AVR and subsequently developed severe prosthetic
mitral regurgitation that was managed with a ‘‘valve-in-
valve’’ TA mitral valve (MV) replacement.CASE REPORT
An 85-year-old man with a complex history notable
for coronary artery disease status post (s/p) multiple
percutaneous coronary interventions and a 2-vessel bypass
14 years previously, MV disease s/p bioprosthetic valve
replacement (concomitant with the bypass), aortic stenosis
s/p TA-AVR 4 months previously, ventricular tachycardia
s/p biventricular implantable cardioverter-defibrillator,
atrial fibrillation (on warfarin), and chronic kidney disease
presented to a community hospital complaining of pro-
gressively worsening dyspnea. The patient underwent
diuresis and ultimately was transferred to our center,
where transthoracic echocardiography revealed new 4þ
mitral regurgitation and thickened, calcified bioprosthetic
mitral cusps.
The patient’s condition deteriorated, and he was
transferred to the cardiac intensive care unit for ionotropic
support and continuous venovenous hemofiltration. An
intra-aortic balloon pump had to be placed, and inhaled
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The Journal of Thoracic and Carcardiogenic shock worsened. His predicted risk of mortality
(Society of Thoracic Surgeons risk score) from conventional
MV replacement was 87%. Given his desire to proceed with
the maximal efforts of care, we brought the patient to the
operating room for emergency TA ‘‘valve-in-valve’’ MV
replacement after he had provided informed consent.
A 10-cm anterolateral incision was made overlying the
ventricular apex. The left ventricle was accessed 1 cm
inferior to the previous TA entry site by way of an
18-gauge needle, through which a guide wire was then
passed. The regurgitant 27-mm bioprosthetic MV was
crossed without difficulty. Using the Seldinger
technique and the Ascendraþ System (Edwards Life-
sciences, Irvine, Calif), a new 26-mm SAPIEN valve
(Edwards Lifesciences) was retrogradely deployed
through the old bioprosthesis. Intraoperative angiography
and transesophageal echocardiography both confirmed
excellent MV bioprosthesis placement with proper
valvular function and trace regurgitation (Figure 1). The
patient was then transported to the cardiothoracic surgery
intensive care unit critically ill but with improved
hemodynamics.
The patient showed remarkable improvement over the
next several days. The intra-aortic balloon pump was
removed on postoperative day (POD) 1, and he was weaned
off the inhaled nitric oxide and vasopressors. His renal
function began to improve, and continuous venovenous
hemofiltration was suspended on POD 9. The patient was
transferred to a step-down unit on POD 15 and was
discharged to a subacute rehabilitation facility on POD
19. His transthoracic echocardiogram at discharge showed
the MV bioprosthesis remained in a good position, with a
valve area of 1.8 cm2 and a gradient of 6 mm Hg; trace
mitral regurgitation was present. At 6 months after surgery,
the patient was walking short distances, denied dyspnea at
rest, and was comfortably living at home. His transthoracic
echocardiogram demonstrated a well-positioned, properly
functioning MV with mild paravalvular regurgitation. He
had no evidence of a ventricular apex aneurysm.DISCUSSION
High-risk patients requiring reoperative valve surgery
in the setting of previous TA-AVR pose a surgicaldiovascular Surgery c Volume 148, Number 5 e209
FIGURE 1. A, Previous mitral valve bioprosthesis with evidence of severe regurgitation on transesophageal echocardiogram. B, New ‘‘valve-in-valve’’
bioprosthesis (arrow) deployed using a transapical transcatheter approach demonstrating nonobstructive flow on transesophageal echocardiogram, with
(C) trace regurgitation.
Case Reportsdilemma: Widely held, largely anecdotal dogma holds that
re-entering the apex in this scenario comes with undue risk
and that redo TA approaches should therefore not be
entertained. To date, only 2 such redo operations have
been described.1,2 The first case involved a reoperative
TA-AVR performed 3 years after the index procedure; the
original TA-placed bioprosthesis had deteriorated, necessi-
tating replacement.1 In the second description, redo
TA-AVR was performed more acutely (ie, 1 day) after
an initial TA-AVR resulted in grade 2 paravalvular
regurgitation.2 Both of these reports used ‘‘valve-in-valve’’
replacements and demonstrated that such repeat operations
are feasible.
The present case is unique in that we performed a
reoperative TA valve replacement with a bioprosthesis
used in the mitral position—a prosthesis actually designed
for the native aortic position. Although surgeons have
already accessed the MV using the TA approach (for both
native and prosthetic valve replacements), none have done
so by re-entering an apex that had previously been subjected
to a TA procedure.3,4e210 The Journal of Thoracic and Cardiovascular SurCONCLUSIONS
A high perioperative risk often precludes conventional
reoperative MV replacement. Moreover, previous TA-
AVR is considered to be a contraindication to redo TA
surgery. We have demonstrated that TA replacement of a
failed MV bioprosthesis can be safely performed in a
patient who had undergone previous TA-AVR. Despite his
precarious risk profile, our patient continues to do well
postoperatively.
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